Investing
Loeb Reiterates Call for PDLI's CEO's Head; Says Company Should Follow MEDI to the Auction Block
Published:
From 13D Tracker
Large PDL BioPharma (Nasdaq: PDLI) shareholder Third Point LLC, run by Daniel Loeb, confirmed what they called a "very disappointing" response to their recent requests and reiterated its demand that CEO Mark McDade step down, citing his misteps including unnecessary spending on the Company’s corporate headquarters (Loeb called it the Taj Mahal) as well as wasteful R&D and SG&A spending.
Third Point requested that the Company founder and board member Laurence Korn be immediately installed as acting chief executive officer and chairman.
ThirdPoint said PDLI’s Board should act in a similar fashion to MedImmune’s (Nasdaq: MEDI) board, which announced last week that they engaged Goldman Sachs to explore a sale of the Company.
Third Point ended saying, "In sum, we ask the Board to look past personal loyalty to Mr. McDade and think objectively about his performance and about the Board’s duty to shareholders. We are confident that you will come to the conclusion that Mr. McDade must go and that an investment bank should be engaged to explore strategic alternatives expeditiously."
Press Release from Third Point
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
